Here are 1-2 brief analogies to describe Bullfrog AI (BFRG):

• Palantir for drug development: Bullfrog AI leverages a sophisticated AI/ML platform, similar to how Palantir uses advanced data analytics for complex problems, but specifically applies it to uncover insights and improve decision-making in the challenging field of therapeutic development.
• The "Moneyball" for pharmaceuticals: Just as the "Moneyball" strategy used data analytics to find undervalued players and optimize baseball team performance, Bullfrog AI uses its AI/ML platform to identify optimal patient populations and development paths for drugs, aiming to "rescue" failed assets or increase the success rate of new ones.

• Contract Services (AI/ML Data Analysis): Provides fee-for-service analysis of complex drug development data using its proprietary bfLEAP™ AI/ML platform for external biopharmaceutical companies at discovery, preclinical, or clinical stages.
• Collaborative Drug Development: Enters into arrangements with biotechnology and pharmaceutical companies to apply its bfLEAP™ platform to drugs in development or those that have failed, earning revenue through cash payments, success fees, and intellectual property rights.
• Drug Asset Enhancement and Divestiture: Acquires rights to drug candidates, including those that have failed late-stage trials or are early-stage, uses its bfLEAP™ platform to optimize their development path and identify specific patient populations, conducts further trials, and then divests the de-risked assets to larger pharmaceutical companies.

1. Biopharmaceutical Companies (Biotechnology and Pharmaceutical Companies): These companies are the primary targets for Bullfrog AI's contract services, which involve providing AI/ML analysis of complex data sets throughout the drug development process. They are also sought for collaborative arrangements involving drugs in development or those that have failed late-stage clinical trials.
2. Large Pharmaceutical Companies: Specifically identified as potential buyers for drug assets that Bullfrog AI acquires, enhances using its bfLEAP™ platform, validates through clinical trials, and then divests.
3. Other Organizations (involved in drug development): This broader category, explicitly mentioned under contract services, includes various entities that may require advanced AI/ML data analysis for drug discovery, preclinical, or clinical stages. This could encompass non-profit organizations or research institutions engaged in therapeutic development.

• Johns Hopkins University Applied Physics Laboratory
• Johns Hopkins University
• George Washington University

Vin Singh
Chairman and CEO

Vin Singh is the Founder, Chairman, and CEO of Bullfrog AI Holdings, Inc. since its inception in August 2017. He is a serial entrepreneur with 25 years of experience in the life sciences and biotechnology industries. Singh founded and built several investor-backed companies, including Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and co-founded MaxCyte Inc. (NASDAQ: MXCT), a cell therapy company. He also served as an executive at GlobalStem Inc. and ThermoFisher Scientific, where he led their global cell therapy services business.

Josh Blacher, MBA
Chief Financial Officer

Josh Blacher is the Chief Financial Officer at Bullfrog AI Holdings, Inc., bringing over two decades of financial leadership in the life science and biotech sectors. His background includes roles as CFO at Predictive Oncology, Rampart Bioscience, and Excision BioTherapeutics, and he has held senior positions at Teva Pharmaceuticals. Blacher has a proven track record in financial stewardship, capital raising, operations, profitability, and deal-making, overseeing SEC reporting and investor relations for both private and publicly traded companies.

Praveen Kudithipudi, MD, MBA
Chief Business Development Officer

Praveen Kudithipudi is the Chief Business Development Officer at BullFrog AI Holdings, Inc. He brings over 19 years of experience spanning life sciences, biotech, bioinformatics, pharmaceutical, and technology sectors.

Antonio V. Montano
Chief Marketing Officer & Growth Strategy Leader

Antonio V. Montano serves as the Chief Marketing Officer & Growth Strategy Leader. His experience includes a mix of life sciences, biotech, bioinformatics, pharmaceutical, and technology sectors, spanning over 19 years.

JT Koffenberger
Chief Information Officer

JT Koffenberger has over 30 years of experience leveraging IT services for business, developing expertise that includes providing advanced solutions.

Key Business Risks for Bullfrog AI (BFRG)

1. Lack of Commercialized Drugs or Regulatory Approvals Leveraging the bfLEAP™ Platform: Bullfrog AI's core business model is built on using its AI/ML platform, bfLEAP™, to improve the success and efficiency of drug development. However, the company explicitly states, "To date, we have not conducted clinical trials on any pharmaceutical drugs and our platform has not been used to identify a drug candidate that has received regulatory approval for commercialization." and "The platform has not yet aided in the development of a drug that has reached commercialization." This means the company has not yet demonstrated the commercial viability or regulatory success of its platform in bringing a drug to market, which is fundamental to its value proposition and future revenue generation.
2. Dependence on Successful Strategic Partnerships, Collaborations, and Acquisitions for Revenue Generation and Drug Development: The company's anticipated revenue streams heavily rely on contract services and collaborative arrangements with biopharmaceutical companies, as well as the acquisition, development, and subsequent divestment of drug assets. The success of these initiatives depends on securing suitable partners and assets, the effective application of the bfLEAP™ platform, successful clinical trials, and the ability to find buyers for divested drug assets. Each of these steps introduces significant external dependencies and inherent risks associated with drug development and market transactions.
3. Significant Capital Requirements and Reliance on Future Revenue Generation: Bullfrog AI has acknowledged, "While we have not generated significant revenues from our AI/ML operations, we anticipate generating revenue in the future..." The company's strategy involves acquiring rights to drug candidates, conducting clinical trials, and continuously evolving its intellectual property and platform, all of which are capital-intensive activities. Without substantial current revenue, the company's ability to fund these operations and achieve its long-term goals is dependent on future funding or the successful execution and commercialization of its initial ventures, posing a financial risk.

Bullfrog AI (BFRG) anticipates its future revenue growth over the next 2-3 years to be driven by three primary strategies:

1. Growth in Contract Services: The company plans to offer its proprietary bfLEAP™ AI/ML platform as a fee-for-service model to biopharmaceutical companies and other organizations. These services will involve analyzing large, complex data sets at the discovery, preclinical, or clinical stages of drug development to predict targets, patterns, relationships, and anomalies. Revenue from this source will include cash fees and potentially rights to new intellectual property generated from the analysis.

2. Expansion of Collaborative Arrangements: Bullfrog AI intends to enter into more collaborative agreements with biotechnology and pharmaceutical companies. These collaborations will focus on drugs in development or those that have failed late Phase 2 or Phase 3 trials, as well as discovery and preclinical stage drugs. Revenue from these arrangements will be a combination of fee-for-service cash payments and success fees based on achieving specific milestones, potentially including fees or legal rights associated with new intellectual property development.

3. Successful Acquisition and Divestment of Drug Assets: A key driver involves acquiring the rights to drugs, particularly those that have failed late-stage clinical trials (Phase 2 or Phase 3), or even preclinical and early clinical drug assets. Bullfrog AI will then utilize its bfLEAP™ platform to determine optimal patient profiles for these drugs, conduct clinical trials to validate these findings, and subsequently divest or sell the "rescued" drug assets back to larger pharmaceutical companies. These transactions are expected to generate revenue through upfront payments, milestone payments tied to clinical success, and royalties on product sales.

Capital Expenditures

• On July 8, 2022, Bullfrog AI entered into an exclusive, worldwide, royalty-bearing license from The Johns Hopkins University Applied Physics Laboratory (JHU-APL) for additional technology developed to enhance the bfLEAP™ platform.
• The company has signed exclusive worldwide license agreements with Johns Hopkins University for a cancer drug targeting glioblastoma, pancreatic cancer, and other cancers.
• An exclusive worldwide license has been signed with George Washington University for a cancer drug targeting hepatocellular carcinoma (liver cancer) and other liver diseases.